Noda M, Tsai S C, Adamik R, Bobak D A, Moss J, Vaughan M
Laboratory of Cellular Metabolism, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.
Biochemistry. 1989 Sep 19;28(19):7936-40. doi: 10.1021/bi00445a057.
Cholera toxin catalyzes the ADP-ribosylation that results in activation of the stimulatory guanine nucleotide-binding protein of the adenylyl cyclase system, known as Gs. The toxin also ADP-ribosylates other proteins and simple guanidino compounds and auto-ADP-ribosylates its AI protein (CTA1). All of the ADP-ribosyltransferase activities of CTAI are enhanced by 19-21-kDa guanine nucleotide-binding proteins known as ADP-ribosylation factors, or ARFs. CTAI contains a single cysteine located near the carboxy terminus. CTAI was immobilized through this cysteine by reaction with iodoacetyl-N-biotinyl-hexylenediamine and binding of the resulting biotinylated protein to avidin-agarose. Immobilized CTAI catalyzed the ARF-stimulated ADP-ribosylation of agmatine. The reaction was enhanced by detergents and phospholipid, but the fold stimulation by purified sARF-II from bovine brain was considerably less than that observed with free CTA. ADP-ribosylation of Gsa by immobilized CTAI, which was somewhat enhanced by sARF-II, was much less than predicted on the basis of the NAD:agmatine ADP-ribosyltransferase activity. Immobilized CTAI catalyzed its own auto-ADP-ribosylation as well as the ADP-ribosylation of the immobilized avidin and CTA2, with relatively little stimulation by sARF-II. ADP-ribosylation of CTA2 by free CTAI is minimal. These observations are consistent with the conclusion that the cysteine near the carboxy terminus of the toxin is not critical for ADP-ribosyltransferase activity or for its regulation by sARF-II. Biotinylation and immobilization of the toxin through this cysteine may, however, limit accessibility to Gsa or SARF-II, or perhaps otherwise reduce interaction with these proteins whether as substrates or activator.
霍乱毒素催化ADP核糖基化反应,导致腺苷酸环化酶系统中刺激性鸟嘌呤核苷酸结合蛋白(称为Gs)的激活。该毒素还能使其他蛋白质和简单胍基化合物发生ADP核糖基化,并使自身的A1蛋白(CTA1)发生自ADP核糖基化。CTA1的所有ADP核糖基转移酶活性都被称为ADP核糖基化因子(ARFs)的19 - 21 kDa鸟嘌呤核苷酸结合蛋白增强。CTA1在羧基末端附近含有一个半胱氨酸。通过与碘乙酰 - N - 生物素基己二胺反应,CTA1通过这个半胱氨酸被固定化,并使产生的生物素化蛋白与抗生物素蛋白 - 琼脂糖结合。固定化的CTA1催化精胺的ARF刺激的ADP核糖基化反应。去污剂和磷脂可增强该反应,但从牛脑中纯化的sARF - II的刺激倍数远低于游离CTA所观察到的。固定化的CTA1对Gsa的ADP核糖基化反应(sARF - II对其有一定增强作用)远低于基于NAD:精胺ADP核糖基转移酶活性所预测的水平。固定化的CTA1催化自身的自ADP核糖基化反应以及固定化抗生物素蛋白和CTA2的ADP核糖基化反应,sARF - II对其刺激作用相对较小。游离CTA1对CTA2的ADP核糖基化作用极小。这些观察结果与以下结论一致:毒素羧基末端附近的半胱氨酸对于ADP核糖基转移酶活性或其被sARF - II调节并非至关重要。然而,通过这个半胱氨酸对毒素进行生物素化和固定化可能会限制对Gsa或sARF - II的可及性,或者可能以其他方式减少与这些蛋白质作为底物或激活剂的相互作用。